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a  b  s  t  r  a  c  t
The  genotype  of  the  hepatitis  C virus  (HCV)  is  an important  indicator  for antiviral  therapeutic  response.
We  hereby  described  development  of  a rapid  HCV  genotyping  approach  that enabled  the  identiﬁcation
of  the  six  most  common  HCV  subtypes  of  Asia,  i.e.,  1a, 1b,  2a, 3a,  3b, and  6a,  in a  single  reaction.  Using
two  dual-labeled,  self-quenched  probes  that  target  the  core  region  of  the  HCV  genome,  the  exact  subtype
could  be accurately  identiﬁed  by  two-melting  temperature  codes  determined  from  the  two  respective
probes  in  a real-time  PCR  assay.  Analytical  sensitivity  studies  using  armored  RNA  samples  representing
each  of the  six  HCV  subtypes  showed  that  5 copies/reaction  of HCV  RNA  could  be detected.  The  assay
was  evaluated  using  244 HCV-positive  serum  samples  and  the  results  were  compared  with  sequencingixed infection
luorescence melting curve analysis
analysis.  Of  the  224  samples,  subtype  3a  (127,  52.3%)  was  the  dominant,  followed  by 1b  (51,  20.9%),  3b
(47,  19.3%),  2a (8,  3.3%),  6a (4,  1.6%)  and  the  least  was  subtype  1a  (1,  0.4%).  Moreover,  6  (2.5%)  mixed
infection  samples  were  also  detected.  These  results  were  fully  concordant  with  sequencing  analysis.  We
concluded  that  this  real-time  PCR-based  assay  could  provide  a rapid  and  reliable  tool  for  routine  HCV
genotyping  in most  Asian  countries.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Hepatitis C virus (HCV) is an important and widely transmitted
irus in the world. Estimates from the World Health Organization
eport that 3.3% (200 million) of the world population is infected
ith HCV (Lavanchy, 2009; Mohd Hanaﬁah et al., 2013; Wands,
004). In China, there are approximately 13 million HCV infected
atients, with prevalence of 1.9%. The prevalence of HCV infections
n Pakistan is higher (4.7%), with about 10 million people currently
arrying HCV (Sievert et al., 2011).
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166-0934/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
HCV is a highly infectious, blood-borne agent that causes liver
related ailments, and a signiﬁcant cause of morbidity and mortality
in the human population. Identiﬁcation of HCV genotype/subtype
is important for therapy and patient management. Recent studies
revealed that there are the 7 major HCV genotypes and 67 subtypes
(Smith et al., 2014).
During the last decade, the standard therapy for chronic hep-
atitis C infection is treatment with pegylated interferon- that is
administrated as a monotherapy or in combination with ribavirin
(Jun et al., 2012; McHutchison et al., 2009). The response rate to
this therapy differs among patients as the HCV genotype is a strong
prognostic factor for sustained virological response (Blum, 2003;
Saracco et al., 2003; Seeff and Hoofnagle, 2003). It is observed that
patients with genotype 2 and 3 have a two- to three-fold higher
response rate than patients infected with genotype 1 (Ghany et al.,
2009; Poynard et al., 1998). Recently, the US Food and Drug Admin-
istration has approved two direct-acting antivirals (DAAs) that have
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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een recommended in combination with pegylated interferon-a
lus ribavirin, which hold great potential in the management of
CV ((Alter and Liang, 2012). Triple combination therapy, includ-
ng either one of the two DAAs telaprevir or boceprevir, is currently
ecommended for the treatment of HCV genotype 1 (Ghany et al.,
011). This new management approach has shown an increased
esponse rate from 35% to 70% and the duration of therapy is
educed from 12 to 6 months. However, these drugs have side
ffects, require effective drug treatment regimes by health pro-
essionals are extremely expensive and are not equally available
orldwide, which limit their use to a great extent. Therefore, in
ost parts of the world particularly in the developing countries,
eg-interferon and ribavirin still remains the therapy of choice
Asselah and Marcellin, 2014; Soriano et al., 2013). Therefore, a
apid, accurate, and affordable HCV genotyping assay for treatment
anagement and patient care is necessary.
Currently, sequence analysis of speciﬁc regions (NS5, core, E1
nd 5′UTR) is considered to be the gold standard for genotyping
Ohno and Lau, 1996). However, alternative methods that offer
apid and cost-effective genotyping are more suitable for clini-
al use. These methods include ampliﬁcation with type-speciﬁc
rimers or type-speciﬁc probes (Okamoto et al., 1992; Qu et al.,
994), restriction fragment length polymorphism (Park et al.,
998), line-probe testing (Stuyver et al., 1996) and heteroduplex
obility analysis (Margraf et al., 2004; White et al., 2000). More
ecently, high throughput methods using matrix-assisted laser
esorption ionization time of ﬂight (MALDI-TOF) technology (Ilina
t al., 2005) and melting curve analysis using LightCycler® systems
Bullock et al., 2002; Haverstick et al., 2004; Schroter et al., 2002)
ere also developed. These methods, nevertheless, have found
imited applications in the developing countries owing to the need
or special and expensive instruments. Two commercial assays, the
ersant HCV genotype 2.0 assay (line probe assay [LiPA] 2.0), based
n reverse hybridization, and the Abbott Realtime HCV genotype II
ssay, are widely used to analyze HCV genotypes. These two assays,
owever, have limitation in identifying HCV genotype 6 (Yang et al.,
014), which is found to increase signiﬁcantly in the past years in
hina (Rong et al., 2014).
We hereby describe a rapid HCV genotyping assay that can dif-
erentiate the six mostly common HCV subtypes, i.e., 1a, 1b, 2a,
a, 3b and 6a, in Asian countries. Using two dual-labeled, self-
uenched probes in a single reaction (Huang et al., 2011), a melting
urve analysis (MCA) run in a real-time PCR machine after PCR gave
 two-melting temperature (Tm) code, by which a certain subtype
f HCV could be identiﬁed. We  studied the analytical sensitivity of
he assay using armored RNA species representing each of the six
ubtypes. We evaluated its performance on a panel of 244 clini-
al samples collected from China and Pakistan and compared the
esults with sequencing analysis.
. Materials and methods
.1. Clinical samples
A total of 244 HCV positive serum samples were collected from
he Sindh and Punjab provinces in Pakistan (141) and from the
outheastern province of Fujian in China (103). Thirty HCV nega-
ive serum samples of healthy persons were provided by the clinical
athology laboratory of the Chinese Traditional Medicine Hospital
f Xiamen, Fujian, China. All the samples were stored at −80 ◦C..2. Preparation of armored HCV RNA
The representative sequences of six HCV subtypes were
etrieved from the HCV database of Los Alamos National Laboratoryal Methods 222 (2015) 85–90
(http://hcv.lanl.gov/content/index) and GenBank (http://www.
ncbi.nlm.nih.gov). The following sequences were used: 1a (HCV-H
M674631), 1b (HEBEI L02836), 2a (AF034629), 3a (HK10 U10197),
3b (ST D11443), and 6a (HK2 U10198). The ∼300-nt long sequences
from the core regions were synthesized using primer F1, F2 and R1
(Supplementary Table S1), and cloned into the pARI-MS2 armored
RNA expression vector. Armored RNA species were expressed,
puriﬁed, and quantiﬁed as described (Cheng et al., 2006).
2.3. Primer and probe design
Primers and probes were designed to target the core region of
the HCV genome (Supplementary Table S1). They included two
forward primers (F1 and F2), one reverse primer (R1), and two
dual-labeled probes (P1 and P2). F1 and F2 were located in the
same region of the core gene but differed with three nucleotides.
Such a design could allow all of the six HCV subtypes (1a, 1b, 2a,
3a, 3b, and 6a) to be ampliﬁed. To facilitate probe binding, two
additional probes, H1 and H2, were designed for P1 and P2, respec-
tively. H1 and H2 help to expose the binding regions to P1 and P2
in a single-stranded conﬁrmation. All primer and probe sequences
were analyzed in BLAST to conﬁrm speciﬁcity.
2.4. HCV RNA extraction and cDNA preparation
HCV RNA was  extracted from 140 L of serum sample using
a QIAamp viral RNA kit (Qiagen, Hilden, Germany). The cDNA
was prepared using PrimescriptTM RT reagent kit (Takara, Dalian,
China).
2.5. Assay procedure
PCR was  performed in a Bio-Rad CFX-96 real-time PCR machine
(Bio-Rad, Hercules, CA). Each 25-L reaction contained 2.5 L of
10× PCR buffer (Takara, Dalian, China), 1.0 U Taq HS DNA poly-
merase (TaKaRa, Dalian, China), 200 M each dNTPs, 200 nM probe
P1, P2, H1 and H2 each, 80 nM primer F1 and F2 each, and 800 nM
R1. To this reaction, 5 L of template cDNA was added. PCR was
carried out by denaturation at 95 ◦C for 3 min  and 60 cycles of 95 ◦C
for 15 s, 50 ◦C for 20 s, and 72 ◦C for 20 s. After PCR, MCA  started
with denaturation at 95 ◦C for 1 min, followed by a temperature
increase from 35 ◦C to 85 ◦C at 0.5 ◦C/step with a 5 s stop between
each step, during which ﬂuorescence was  acquired from FAM and
ROX channels. The melting curve was  obtained by plotting the neg-
ative derivative of ﬂuorescence with respect to temperature versus
temperature (−dF/dT) and the Tm values were obtained by auto-
matic peak calling from the melting curve. For each sample, two Tm
values from both the FAM and ROX channels were obtained.
2.6. Analytical sensitivity study
To determine the limit of detection (LOD) of the assay, each
armored RNA species was  serially diluted with pooled HCV neg-
ative serum to concentrations of 105, 104, 103, 102, 101, and
100 copies/L, respectively. The extracted RNA was measured in
triplicate. The results of this study were also used to determine the
reproducibility of the Tm measurement.
2.7. Study of mixed genotypes
To study mixed infection, armored RNA of two subtypes were
separately diluted to 106 copies/L with pooled HCV negative
serum, The two RNA species were then mixed in various ratio (i.e.,
100:0, 97:3, 95:5, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70,
20:80, 10:90, 5:95, 3:97, and 0:100). The RNA was extracted and
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Fig. 1. Schematic illustration of a two-Tm code assay. Upper panel: The core region
of  the HCV genome was chosen to design primers and probes. Two forward primers,
F1  and F2, which share the same binding region but differ by 3 bases, were designed
to  cover all the six HCV subtypes. Two probes, P1 and P2, which have different
mismatched bases (small vertical lines) for the six HCV subtypes in their probe
binding regions, were designed to harbor ﬂuorophores, FAM and ROX, respectively.
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Fig. 2. Simultaneous detection of HCV armored RNA 1a and 2a genotypes in mixed
infections. Two co-existing genotypes were detected in the same channel. Melting
curves of artiﬁcial armored RNA templates containing two  HCV genotypes of various
percentage ratios (100:0, 97:3, 95:5, 90:10, 80:20, 70:30, 60:40, 50:50, 40:60, 30:70,ower panel: Melting curves of P1 and P2 were used to generate Tm values for the
ix  HCV subtypes. For each subtype, two Tm values were obtained from P1 and P2,
espectively, and thereby a two-Tm code was generated.
ubjected to genotyping assay. Two mixed subtypes, 1a plus 2a,
nd, 1b plus 3b were studied, respectively.
.8. Sequence and statistical analysis
The subtype of each clinical sample was determined by sequenc-
ng analysis using primers F1 and R1. The PCR components were
s follows. Each 25-L reaction contained 2.5 L of 10× PCR
uffer (Takara), 1.0 U Taq HS DNA polymerase, 200 M each dNTPs,
.08 M primer F1, 0.8 M R1 and 5 L of template cDNA. Ther-
al  conditions were as follows: PCR was carried out by step 1,
enaturation at 95 ◦C for 3 min, step 2, 95 ◦C for 15 s, 50 ◦C for 20 s,
nd 72 ◦C for 20 s repeat 60 cycles. PCR products were subjected
o bi-directional sequencing (Majorbio, Shanghai, China). The
equencing results were analyzed with ClustalX software (http://
ww.clustal.org/). Consistency between real time-PCR/MCA and
equencing results was assessed using the k coefﬁcient, with k val-
es between 0.61 and 0.80 being good concordance (Thompson
nd Walter, 1988). Statistical analysis was performed using SPSS
version 13.0, SPSS Inc., Chicago, IL).
Phylogenetic analysis was performed by distance matrix and
eighbor joining comparison of a 230 nucleotide sequences of core
egions using the MEGA6 software (Tamura et al., 2013).
. Results
In this study, a two-Tm codes strategy for HCV genotyping was
eveloped. The two probes could conﬁrm the typing result with
ach other considering the occurrence of potential SNPs in the
robe-binding region. Thus, such a two-Tm code ensures the accu-
acy of the typing result (Fig. 1).
.1. Analytical performanceThe analytical study using armored RNA species extracted from
he negative pooled serum showed that all samples displayed char-
cteristic ﬂuorescence peaks at each titer. The limit of detection20:80, 10:90, 5:95, 3:97, 0:100) were tested. The overall template concentration
was 106 copies per reaction. Diethylpyrocarbonate (DEPC) Water was used as no
template control (NTC, gray line).
was determined to be 1 × 100 copy/L (5 copies/reaction) for each
subtype (Supplementary Fig. S1). The Tm values obtained for each
subtype and the reproducibility of Tm measurement are listed in
Table 1. The Tm difference between each subtype detected by P1
ranged from 9.5 ◦C (between 2a and 1b) to 1.9 ◦C (between 2a and
6a). The smallest difference was larger than 1 ◦C, which was  resolv-
able by the machine. Similarly, the smallest Tm difference between
each subtype detected by P2 was  1.8 ◦C (between 2a and 6a), which
was also larger than 1 ◦C. Moreover, the SD values for all of the sub-
types determined from both P1 and P2 ranged from 0 to 0.5 ◦C,
which are lower than the resolvable 1 ◦C. These results demon-
strated that the six HCV subtypes can be differentiated by either
P1 or P2 through Tm measurement and the differentiation can be
ensured by the high reproducibility of Tm values.
3.2. HCV subtypes detection in mixed infections
As shown in Fig. 2, our assay could detect the highest and the
lowest levels (3%) of viral RNA in the in vitro mimic  of mixed sub-
type 1a and 2a when the overall copy number is 106 copies per
reaction. Similar results were obtained with subtype 1b and 3b.
These data indicate that our PCR/MCA method can detect mixed
infections between in a wide range.
3.3. Clinical samples detection
Of 244 clinical samples, 127 (52.3%) were determined to be sub-
type 3a, 51 (20.9%) were subtype 1b, 47 (19.3%) were subtype 3b,
8 (3.3%) were subtype 2a, 4 (1.6%) were subtype 6a, and 1 (0.4%)
was subtype 1a. Six (2.5%) samples were quasi-species samples
including 4 mixed subtypes 3a and 3b, and 2 mixed subtypes 3a and
1b (Supplementary Fig. S2). Sequencing analysis was performed in
parallel for the above samples and the results showed that a 100%
agreement rate was achieved between the two  methods (Table 2).
Results from P1 and P2 were fully concordant with each other
(Table 1). To further verify all six subtypes of HCV, phylogram was
constructed with the six subtype’s standard reference sequences
for the core region (Supplementary Fig. S3). The core sequences of
230 samples and the standard reference sequences of 1a, 1b, 2a,
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Table  1
Tm values of armored RNA and clinical positive samples.
Subtypes Armored RNA (◦C, n = 10) Clinical samplesa (◦C, n = 244)
P1 P2 P1 P2
Mean SD Mean SD Mean (n) SD Mean (n) SD
1a 56.6 0.5 52.5 0.0 56.5 (1) NA 52.5 (1) NA
1b  65.6 0.23 56.5 0.23 65.7 (53) 0.31 56.4 (53) 0.29
2a  46.1 0.17 62.3 0.22 46.1 (8) 0.16 62.6 (8) 0.99
3a  52.2 0.28 54.4 0.37 52.3 (133) 0.29 54.8 (133) 0.53
3b  58.5 0.38 45.8 0.37 58.6 (51) 0.36 45.5 (51) 0.33
6a  48.0 0.0 60.5 0.5 47.6 (4) 0.22 60.7 (4) 0.56
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CD, standard deviation; NA, not available.
a The mean Tm of each subtype obtained from the 244 clinical samples including
umber of that subtype given in the parentheses.
a, 3b, and 6a were grouped in six clusters. The six mixed infec-
ion samples were excluded from this analysis. The result showed
hat the genotypes identiﬁed by the phylogenetic analysis were
dentical to those assigned by melting curve and blast analysis.
The mean Tm values of the clinical samples detected by both
robes were within the Tm range of the corresponding armored
CV RNA (Fig. 3). Of the 51 samples of subtype 3b, three sam-
les gave Tm value between 59.5 ◦C and 60.5 ◦C, which were larger
han the standard armored RNA (Tm = 58.5 ◦C). Sequencing results
evealed 4–5 SNPs present within P1 binding region (Supplemen-
ary Table S2). For these three samples, sequencing analysis also
isplayed the presence of SNPs in P2 binding region on the terminal
equence but no Tm, shift was observed. Of the 127 samples of 3a,
wo samples showed a 1.5 ◦C difference from the standard armored
NA Tm value detected by P1. Again, sequencing analysis revealed
hat this Tm shift was caused by SNPs present in the probe binding
egion (Supplementary Table S2). Taken together, all of the detected
NPs induced only insigniﬁcant Tm shift in one probe and no shift
n another probe, thus exerting no inﬂuence on the subtype calling.
. Discussion
We  successfully developed a rapid real-time PCR-based melt-
ng curve analysis assay that can accurately differentiate the six
ommon Asian HCV subtypes, 1a, 1b, 2a, 3a, 3b and 6a, in a sin-
le reaction. Using a unique two-Tm code, derived from two probes
inding to the core region of HCV, the six subtypes could accu-
ately be discriminated. The detection results of 244 HCV-positive
amples were fully concordant with sequencing analysis, demon-
trating the accuracy of the assay.
Determination of HCV genotypes or subtypes has become
ncreasingly important during the past 20 years for prediction of
he clinical course and outcome of antiviral therapy (Schroter et al.,
002). However, many existing methods are laborious and expen-
ive, leading to limited usage in daily routine diagnostics, mainly
ue to the use of complex post-PCR analysis. In this scenario, real
ime PCR-based melting curve analysis has gained popularity in
able 2
omparison of subtype results between PCR/MCA assay and sequencing analysis.
HCV subtypes No. of subtypes 
MCA  Sequencing MCA  and sequencing
1a 1 1 1 
1b  53 53 53 
2a  8 8 8 
3a  133 133 133 
3b  51 51 51 
6a  4 4 4 ixed infection samples in total 250 Tm observations were calculated based on the
recent years. In a previous study (Bullock et al., 2002), a single set of
ﬂuorescence resonance energy transfer (FRET) probes was used to
distinguish HCV types 1a/b, 2a/c, 2b, 3a, and 4. The results demon-
strated that melting analysis could identify genotype 1 samples
with high speciﬁcity. A validation study of this assay (Haverstick
et al., 2004) over a period of 23 months conﬁrmed that it could easily
distinguish HCV genotype 1 infection from non-genotype 1 infec-
tions, and proved to be a fast, reliable and relatively inexpensive
format. In another study (Schroter et al., 2002), three hybridization
probes were used successfully to identify HCV genotypes 1, 2, 3,
and 4 in a single reaction. So far, however, no melting curve analysis
was reported to identify those dominant genotypes or subtypes in
Asian countries. Our assay thus met  this clinical demand. Unlike the
FRET probes previously used, the self-quenched probes are advan-
tageous in their compatibility with different real-time instruments
(Huang et al., 2011), making our assay more accessible in different
clinical settings.
Currently, various regions of HCV genome including 5′UTR, E1,
NS4, NS5 and core region have been used for genotyping or sub-
typing of HCV (Laperche et al., 2005; Pawlotsky, 1999). Among
them, the 5′UTR is the most conserved and the most widely used
for HCV typing. However, the 5′UTR is devoid of sequence variabil-
ity and gives occasional subtyping errors (Ansari et al., 2012; Chen
and Weck, 2002; Tamalet et al., 2003). For example, genotype 6, a
widely spread genotype in Asia, is often poorly discriminated from
other types. By contrast, the E1, NS4 and NS5 regions are too vari-
able to be suitable for subtype discrimination (Lole et al., 2003).
Increasing studies have recommended the use of the core region
for genotype/subtype identiﬁcation as it exhibits greater sequence
variability than the 5′UTR but is conservative enough within one
subtype (Ansari et al., 2012; Bukh et al., 1995; Lole et al., 2003).
Examples have shown that accurate typing could be achieved by
including the core region (Ansari et al., 2012; Bouchardeau et al.,
2007; Idrees, 2008). Moreover, a comparison study of core, NS5B
sequence analysis and line probe assay showed that the ampliﬁca-
tion rate of the core region was higher than that of NS5B with the
same viral load, suggesting that the ampliﬁcation rate of subge-
nomic regions was  not only associated with viral load but also with
No. of discrepant results Agreement (%)  value (95% CI)
0 100 1.000 (1.000–1.000)
0 100 1.000 (1.000–1.000)
0 100 1.000 (1.000–1.000)
0 100 1.000 (1.000–1.000)
0 100 1.000 (1.000–1.000)
0 100 1.000 (1.000–1.000)
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Fig. 3. Histogram illustrating the spread (interval) and range of each genotype-speciﬁc Tm on P1 and P2 for 244 observations on 244 samples with genotypes conﬁrmed by
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cequencing. *On P1 two samples of 3a showed 1.5 ◦C Tm value shift and three samp
equence conservation. Since the core region was more conserva-
ive than NS5B, it was recommended to be the region of choice for
enotyping of HCV (Cai et al., 2013).
In our assay, the primers were designed to be speciﬁc to the
ore region of HCV. To avoid possible typing error caused by the
ccurrence of potential single nucleotide polymorphic (SNP) sites
n the probe binding region, two probes were used to conﬁrm
he typing results with each other. Five samples indeed harbored
NPs in the P1 binding region. Although the produced small Tm
hift exerted no effect on the identiﬁcation of the subtype by
1, a double check by P2 ensured its correctness (Supplementary
able S2).
One distinct advantage of our assay is its capability of detecting
ixed infection of HCV species. It has been reported that mixed-
enotype infections occur only in a limited number of samples,
ut with elevated mixed infection prevalence in multiple expo-
ure groups, such as injection drug users, hemophiliacs, patients
n chronic hemodialysis, and patients having multiple transfusions
Aitken et al., 2004; Qian et al., 2000). However, many currently
vailable assays, including direct sequencing usually cannot assess
he true prevalence of mixed-genotype infections, since they are
xclusively designed to detect the dominant HCV genotype in the
iral population and those minor population with percentage lower
han 20–30% could be missed (Eyster et al., 1999; Lau et al., 1995).
heoretically, genotype-speciﬁc real-time PCR has much greater
ensitivity to detect mixes since it is quantitatively linear over 6–7
ogs. However, the cross-reactivity and different ampliﬁcation efﬁ-
iencies between genotypes signiﬁcantly prevent the use of this
pproach to detect mixed infections (Cook et al., 2006). By compari-
on, our assay could detect mixed infection where the percentage of
he minor population was as low as 3%. Among the 244 clinical sam-
les, six (2.5%) samples were detected to be mixed infections and
he results were fully matched with sequencing analysis, thereby
emonstrating the inherent potential of the assay to detect the
ixed-genotype infection.
In conclusion, the melting curve analysis developed here is accu-ate in the differentiation of the six common Asian subtypes of HCV.
oreover, it can detect mixed genotypes in one sample. It is easy-
o-use, rapid, and compatible with real-time PCR machine. Thus, it
ould be recommended for clinical use in Asian countries.b subtypes showed the 1.5–2.0 ◦C Tm value shift from standard armored RNA.
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